Clinical trials: Estrogen Receptor- Negative Breast Cancer
Women With ER Positive Breast Cancer Taking (AI) w Joint Discomfort and Stiffness
The Effect of an Exercise Program in Breast Cancer Patients With Joint Pain While Taking Aromatase Inhibitors.
The objective of this study is to determine if patients taking aromatase inhibitors (AI), who are experiencing joint discomfort and stiffness, would have reduction in this discomfort and stiffness by participating in a directed…
- Trial name
- NCT02057536
- Testing
- Arm A Directed exercise program, Observation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Christiana Care Health Services
Breast Cancer
A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer
This is a Phase II, randomised, double-blind, placebo-controlled study. Subjects with histologically-confirmed oestrogen receptor negative (ER-), progesterone receptor negative (PgR-) primary breast cancer breast cancer will be…
- Trial name
- NCT00252811
- Testing
- Gefitinib
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Breast Cancer
Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer
The purpose of this study is to determine whether the combination of docetaxel and carboplatin is an effective treatment for patients with triple negative breast cancer.
- Trial name
- CADENCE (NCT02547987)
- Testing
- Docetaxel, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Mothaffar Rimawi
Recurrent Breast Cancer
A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer
The purpose of this study is to find out what effects this new drug foretinib has on this type of breast cancer, called "triple negative" breast cancer because the cancer tissue is estrogen, progesterone and HER2 receptor…
- Trial name
- IND197 (NCT01147484)
- Testing
- Foretinib
- Where
- 9 sites in Canada
- Volunteers
- 47 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer, Early Breast Cancer
Independent, External, Blinded Retrospective Validation of an AI-based Prognostic Assay in ER-Positive/HER2-Negative Early Breast Cancer
This retrospective observational study evaluates the prognostic performance of a locked Artificial Intelligence (AI)-based assay in patients with Estrogen Receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2…
- Conditions
- Breast Cancer, Early Breast Cancer, ER-Positive HER2-Negative Breast Cancer
- Trial name
- NCT07541703
- Testing
- Locked AI-based prognostic assay
- Where
- Austria
- Volunteers
- 2,200 people
- Sponsor
- Spotlight Medical
Cancer of the Breast, Breast Cancer
CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)
The goal of this clinical study is to determine the safety, pharmacokinetics, pharmacodynamics and efficacy and activity of seviteronel, a lyase-selective inhibitor of CYP17, in patients with advanced breast cancer.
- Conditions
- Cancer of the Breast, Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- Trial name
- CLARITY-01 (NCT02580448)
- Testing
- Seviteronel
- Where
- 36 sites in United States
- Volunteers
- 175 people
- Sponsor
- Innocrin Pharmaceutical
Breast Cancer Female
PreOperative Endocrine Therapy for Individualised Care With Abemaciclib
POETIC-A is a phase 3 trial which targets post-menopausal primary breast cancer patients with a high 5-year risk of relapse as determined by a high Ki67 after 2 weeks aromatase inhibitor therapy pre-surgery.
- Trial name
- POETIC-A (NCT04584853)
- Testing
- Abemaciclib, Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)
- Where
- 62 sites in United Kingdom
- Volunteers
- 123 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Metastatic Breast Cancer
Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
This is an open-label, multicenter, single-arm safety study evaluating the safety and tolerability of the lasofoxifene and abemaciclib combination for the treatment of pre- and postmenopausal women with locally advanced or…
- Trial name
- ELAINEII (NCT04432454)
- Testing
- Lasofoxifene and abemaciclib (VERZENIO (R)).
- Where
- 16 sites in United States
- Volunteers
- 29 people
- Sponsor
- Sermonix Pharmaceuticals Inc.
ER Positive, HER2 Negative Breast Cancer
Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women
This is a phase II study evaluating the efficacy and safety of the pre-operative use of letrozole plus PD 0332991 (combination therapy)
- Trial name
- NCT01709370
- Testing
- Letrozole, PD 0332991
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Organisation for Oncology and Translational Research
Breast Cancer
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
The study will evaluate the safety and efficacy of datopotamab deruxtecan (also known as Dato-DXd, DS-1062a), when compared with Investigator's choice of standard of care single-agent chemotherapy (eribulin, capecitabine…
- Trial name
- NCT05104866
- Testing
- Dato-DXd, Capecitabine, Gemcitabine
- Where
- 167 sites in United States, Argentina and 18 more
- Volunteers
- 732 people
- Sponsor
- AstraZeneca
Breast Neoplasms
The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer
This is an open-label, single arm, phase II trial to evaluate the efficacy and safety of 500mg Fulvestrant (Faslodex®) in ESR1 mutated postmenopausal women with hormone receptor positive, HER2 negative locally advanced or…
- Trial name
- NCT03202862
- Testing
- Fulvestrant
- Volunteers
- 50 people
- Sponsor
- Fudan University
Breast Cancer, HER2-negative Breast Cancer
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor-positive, HER2-negative, FGFR-altered…
- Conditions
- Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
- Trial name
- NCT04504331
- Testing
- Infigratinib, Tamoxifen, Omnipaque 350
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jennifer Lee Caswell-Jin
Receptors, Estrogen, Genes, Erbb-2
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2…
- Conditions
- Receptors, Estrogen, Genes, Erbb-2, Breast Neoplasms
- Trial name
- NCT04288089
- Testing
- Palbociclib (75, 100, 125 milligram [mg]), H3B-6545 (150, 300, 450 mg)
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 31 people
- Sponsor
- Eisai Inc.
Breast Neoplasms
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
This study is being carried out to see if ZD1839 is effective in treating metastatic breast cancer in combination with Nolvadex, and if so, how it compares with Nolvadex alone.
- Trial name
- NCT00229697
- Testing
- Gefitinib, Tamoxifen
- Where
- 55 sites in United States, Argentina and 10 more
- Volunteers
- 317 people
- Sponsor
- AstraZeneca
Breast Cancer
Informative Tools to Optimize Neoadjuvant Therapy in ER Positive, HER2 Negative Breast Cancers
This study evaluates the addition of Ki-67, Oncotype DX and MRI in the treatment of early stage breast cancer with neoadjuvant treatment. All enrolled patients will have Ki-67 and Oncotype AND/OR an MRI before and after surgery.
- Trial name
- ER (NCT03790813)
- Testing
- Intervention 1, Intervention 2
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Breast Cancer
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Taxanes (such as paclitaxel) are highly active to treat breast cancer. Abraxane® (nanoparticle albumin-bound paclitaxel) compared to standard paclitaxel improves efficacy and tolerability.
- Trial name
- ABC (NCT00479674)
- Testing
- Abraxane, Bevacizumab, Carboplatin
- Where
- 4 sites in United States
- Volunteers
- 41 people
- Sponsor
- Duke University
Breast Cancer, Estrogen Receptor Negative Neoplasm
Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of nab-PTX and trastuzumab for ER negative and HER2 positive operable (tumor size of 3cm or less and N0) breast cancer.
- Conditions
- Breast Cancer, Estrogen Receptor Negative Neoplasm, HER-2 Positive Breast Cancer
- Trial name
- NCT02598310
- Testing
- nab-paclitaxel, Trastuzumab
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Osaka Medical College
Breast Cancer
STRIDE - STimulating Immune Response In aDvanced brEast Cancer
EMD Serono has decided to permanently terminate the trial EMR 200038-010 (STRIDE) in the indication of breast cancer following the clinical hold on the investigational new drug application for tecemotide (L-BLP25).
- Trial name
- STRIDE (NCT00925548)
- Testing
- Tecemotide (L-BLP25) and Hormonal Treatment, cyclophosphamide, sodium chloride (NaCl)
- Where
- 29 sites in United States, Australia and 10 more
- Volunteers
- 16 people
- Sponsor
- EMD Serono
Advanced Breast Cancer, ER-positive Breast Cancer
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
This trial will study a type of advanced breast cancer (ABC) defined as endocrine receptor (ER)-positive/human epidermal growth factor receptor 2(HER2)-negative and estrogen receptor 1 (ESR1)-mutated.
- Conditions
- Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation
- Trial name
- ADELA (NCT06382948)
- Testing
- Everolimus, Elacestrant, Auxiliary Medicinal Product - Dexamethasone
- Where
- 104 sites in Austria, Brazil and 7 more
- Volunteers
- 300 people
- Sponsor
- MedSIR
Breast Cancer
A Study of ZN-c5 in Participants With Breast Cancer
This is a Phase 1 open-label, multicenter study to evaluate biomarkers for ZN-c5 in subjects with breast cancer
- Trial name
- NCT04176757
- Testing
- ZN-c5
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 35 people
- Sponsor
- Zeno Alpha Inc.